FTSE 100 bargains! 3 I’d buy in my ISA

I think we are seeing a great opportunity in the FTSE 100, and I’d put these three tempting investments in my Stocks and Shares ISA.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

I’ve been searching the FTSE 100 index for bargains, armed with my refreshed Stocks and Shares ISA allowance of £20,000.

I see two types of potential bargains in the current crisis. Firstly, there are those companies with operations largely unaffected by the economic shutdown. Sometimes such defensive firms have seen their share prices marked down by the market regardless.

Secondly, there are those companies that have seen their businesses greatly affected. Those stocks have fallen a long way. But I reckon there are decent opportunities among both types of share.

Pharmaceuticals

GlaxoSmithKline (LSE: GSK) strikes me as a good example of a firm operating in a defensive sector that’s likely to be less affected by the crisis.

On Tuesday, the company released an update describing a proposed collaboration with Sanofi to fight Covid-19.” The idea is the two firms will combine their “innovative” technologies to develop an “adjuvanted” vaccine for the disease. 

They expect their candidate vaccine to enter clinical trials in the second half of 2020. If it works, the vaccine will likely be available for use around a year later

Meanwhile, it’s hard for me to imagine the demand for GlaxoSmithKline’s medicines and treatments drying up. My guess is that people will keep using their medication regardless of the pandemic. Indeed, the company has a decent multi-year record of steady and rising cash flow, which looks set to continue.

I see the recent weakness in the share price as an opportunity to pick up some of the stock on better terms.

Plumbing and heating products

Plumbing and heating products supplier Ferguson (LSE: FERG) updated the market on 17 March with its half-year results report. The company said then that it was too early to understand how the unfolding coronavirus crisis would affect trading.

But the stock market has made its own judgement. At 5,188p, the share price is more than 30% down from the level it achieved in mid-February. And that’s after bouncing back a fair bit during March.

I’m optimistic about Ferguson’s business. After the recession following the credit crunch and financial crisis just over a decade ago, the company’s operations recovered well and expansion continued. I think the firm serves a resilient sector and is doing a good job of consolidating a fragmented industry.

In the report, the directors expressed an optimistic outlook for the long-term success of the company. I think the stock could make a decent vehicle for riding the recovery after this crisis, just as it did after the last one.

Finally, I promised three FTSE 100 bargains in this article’s headline. And my third choice is the index itself. Because the FTSE 100 is packed with the shares of cyclical companies, I reckon it has good bounce-back potential. So I reckon a FTSE 100 index tracker fund is an attractive proposition right now.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Kevin Godbold has no position in any share mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »